TY - JOUR
T1 - Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation
AU - Weng, Tingting
AU - Ko, Junsuk
AU - Masamha, Chioniso P.
AU - Xia, Zheng
AU - Xiang, Yu
AU - Chen, Ning yuan
AU - Molina, Jose G.
AU - Collum, Scott
AU - Mertens, Tinne C.
AU - Luo, Fayong
AU - Philip, Kemly
AU - Davies, Jonathan
AU - Huang, Jingjing
AU - Wilson, Cory
AU - Thandavarayan, Rajarajan A.
AU - Bruckner, Brian A.
AU - Jyothula, Soma S.K.
AU - Volcik, Kelly A.
AU - Li, Lei
AU - Han, Leng
AU - Li, Wei
AU - Assassi, Shervin
AU - Karmouty-Quintana, Harry
AU - Wagner, Eric J.
AU - Blackburn, Michael R.
N1 - Publisher Copyright:
Copyright: © 2019, American Society for Clinical Investigation.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a poor prognosis and few treatment options. Pathological remodeling of the extracellular matrix (ECM) is a key factor that drives the disease pathogenesis, although the underlying mechanisms remain unknown. Alternative polyadenylation (APA) has recently been shown to play a major role in cellular responses to stress by driving the expression of fibrotic factors through the alteration of miRNA sensitivity, but a connection to IPF has not been established. Here, we demonstrated that CFIm25, a global regulator of APA, was downregulated in the lungs of patients with IPF and mice with pulmonary fibrosis, with its expression selectively reduced in α–smooth muscle actin–positive (α-SMA–positive) fibroblasts. Following CFIm25 knockdown in healthy human lung fibroblasts, we identified 808 genes with shortened 3′-UTRs, including those involved in the TGF-β signaling pathway, the Wnt signaling pathway, and cancer pathways. The expression of key profibrotic factors was suppressed by CFIm25 overexpression in IPF fibroblasts. Finally, we demonstrated that deletion of CFIm25 in fibroblasts or myofibroblast precursors using either the Col1a1 or the Foxd1 promoter enhanced pulmonary fibrosis after bleomycin exposure. Collectively, our results identified CFIm25 downregulation as an important mechanism for elevating profibrotic gene expression in pulmonary fibrosis.
AB - Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a poor prognosis and few treatment options. Pathological remodeling of the extracellular matrix (ECM) is a key factor that drives the disease pathogenesis, although the underlying mechanisms remain unknown. Alternative polyadenylation (APA) has recently been shown to play a major role in cellular responses to stress by driving the expression of fibrotic factors through the alteration of miRNA sensitivity, but a connection to IPF has not been established. Here, we demonstrated that CFIm25, a global regulator of APA, was downregulated in the lungs of patients with IPF and mice with pulmonary fibrosis, with its expression selectively reduced in α–smooth muscle actin–positive (α-SMA–positive) fibroblasts. Following CFIm25 knockdown in healthy human lung fibroblasts, we identified 808 genes with shortened 3′-UTRs, including those involved in the TGF-β signaling pathway, the Wnt signaling pathway, and cancer pathways. The expression of key profibrotic factors was suppressed by CFIm25 overexpression in IPF fibroblasts. Finally, we demonstrated that deletion of CFIm25 in fibroblasts or myofibroblast precursors using either the Col1a1 or the Foxd1 promoter enhanced pulmonary fibrosis after bleomycin exposure. Collectively, our results identified CFIm25 downregulation as an important mechanism for elevating profibrotic gene expression in pulmonary fibrosis.
UR - http://www.scopus.com/inward/record.url?scp=85062416392&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062416392&partnerID=8YFLogxK
U2 - 10.1172/JCI122106
DO - 10.1172/JCI122106
M3 - Article
C2 - 30830875
AN - SCOPUS:85062416392
SN - 0021-9738
VL - 129
SP - 1984
EP - 1999
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 5
ER -